Proteasome 20S subunit beta type-5 and Proteasome 20S subunit beta type-8 (chymotrypsin-like active sites) (PSMB5 and PSMB8)

The 20S proteasome core is a barrel-shaped multi-subunit enzyme complex that serves as the catalytic engine of the ubiquitin-proteasome system (UPS) (UniProt P28074). It is composed of four stacked rings, with the two inner beta-rings containing the proteolytic active sites. The β5 (constitutive) and β5i (immunoproteasome) subunits are responsible for the chymotrypsin-like (CT-L) activity, which is the rate-limiting step in protein degradation and the primary target for clinical proteasome inhibitors (StatPearls, Proteasome Inhibitors). In cancer cells, particularly multiple myeloma, inhibition of these sites causes a toxic accumulation of misfolded proteins, leading to endoplasmic reticulum stress and apoptosis (NIH/NCBI, Role of Proteasome in Cancer). Beyond oncology, the β5i subunit (LMP7) plays a crucial role in processing MHC class I antigens, making it a target for inflammatory and autoimmune research (UniProt P28062). Drugs like bortezomib and carfilzomib exert their therapeutic effects by binding to the N-terminal threonine residue of these subunits (PubChem, Bortezomib). This targeted inhibition disrupts cellular homeostasis and prevents the degradation of regulatory proteins like IκB, thereby inhibiting the NF-κB pathway (PubMed, PMID: 15123519). The distinction between the constitutive β5 and the inducible β5i allows for the development of selective inhibitors that may reduce systemic toxicity while maintaining efficacy in immune-related pathologies.

Other names

β5 subunitβ5i subunitLMP7PSMB5PSMB8Chymotrypsin-like catalytic site20S proteasome beta 520S proteasome beta 8Large multifunctional peptidase 7

Inhibition of the threonine protease activity at the β5 and β5i subunits of the 20S proteasome, preventing the degradation of polyubiquitinated proteins and inducing apoptosis.